Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hoechst Marion Roussel Amaryl Sales Reach $62 Mil. In Second Quarter

Executive Summary

Worldwide sales of Hoechst Marion Roussel's Amaryl sulfonylurea treatment for type 2 diabetes increased by 77% in the second quarter to $62 mil. (EURO 58 mil.), the company reported in an Aug. 4 statement on financial results.
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS034634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel